|Dr. Mark Pruzanski||Founder, CEO, Pres & Director||1.04M||7.64M||1968|
|Mr. Sandip S. Kapadia||CFO, Treasurer & Principal Accounting Officer||282.06k||N/A||1970|
|Dr. David Shapiro M.D., Ph.D.||Chief Medical Officer||688.88k||295.76k||1954|
|Ms. Lisa Bright B.Sc.||Pres of International||614.81k||N/A||1968|
|Mr. Jerome B. Durso||Chief Operating Officer||N/A||N/A||1968|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 7.